Beauty Health (SKIN) Expected to Announce Earnings on Tuesday

Beauty Health (NASDAQ:SKIN) is anticipated to issue its quarterly earnings data before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $78.02 million for the quarter.

Beauty Health Trading Down 13.3 %

Beauty Health stock opened at $1.28 on Tuesday. The company has a quick ratio of 5.57, a current ratio of 6.56 and a debt-to-equity ratio of 9.23. The firm has a 50-day moving average price of $1.62 and a two-hundred day moving average price of $1.59. The firm has a market capitalization of $158.26 million, a price-to-earnings ratio of -3.04 and a beta of 0.82. Beauty Health has a 52-week low of $0.91 and a 52-week high of $5.17.

Analyst Ratings Changes

Separately, Canaccord Genuity Group boosted their target price on shares of Beauty Health from $1.25 to $1.75 and gave the company a “hold” rating in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, Beauty Health presently has a consensus rating of “Hold” and a consensus target price of $2.55.

About Beauty Health

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.